Sugi Predict

Sugi Predict / Compounds / SCHEMBL996002

SCHEMBL996002

SCHEMBL996002

CN1CCC2(CC1)CN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ ACACB O00763 5/20 0.46
▸ GPR183 P32249 1/20 0.46
▸ SCD5 Q86SK9 1/20 0.44
▸ CYP11B2 P19099 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ HDAC2 Q92769 2/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ NR1H2 P55055 1/20 0.39
▸ SPR P35270 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18390155 0.92 CYP11B2 (0.51) USP2SMN1; SMN2ACACBGPR183SCD5
SCHEMBL19158577 0.92 USP2 (0.46) USP2SMN1; SMN2ACACBGPR183SCD5
SCHEMBL18390378 0.90 CYP3A4 (0.49) USP2SMN1; SMN2ACACBGPR183SCD5
SCHEMBL1779347 0.88 USP2 (0.51) USP2SMN1; SMN2CYP11B2HPGDEPHX2
SCHEMBL31209914 0.87 ACACB (0.42) USP2SMN1; SMN2ACACBGPR183SCD5
SCHEMBL18390387 0.87 CYP3A4 (0.50) USP2SMN1; SMN2ACACBSCD5CYP11B2
SCHEMBL16573803 0.87 USP2 (0.48) USP2SMN1; SMN2ACACBGPR183SCD5
SCHEMBL17411222 0.86 USP2 (0.51) USP2SMN1; SMN2ACACBGPR183SCD5
SCHEMBL18389855 0.86 CYP3A4 (0.59) USP2SMN1; SMN2ACACBSCD5CYP11B2
SCHEMBL1299342 0.85 USP2 (0.58) USP2SMN1; SMN2ACACBSCD5CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 — — US disclosed
EP-4182308-B1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-09-04 — — EP disclosed
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-18 — — US disclosed
EP-4182308-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-05-24 — — EP disclosed
CN-116096719-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2023-05-09 — — CN disclosed
WO-2022253309-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF 首药控股(北京)股份有限公司 2022-12-08 — — WO disclosed
WO-2022013307-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-01-20 — — WO disclosed
EP-3426664-B1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-06-30 — — EP disclosed
EP-3322706-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-11-11 — — EP disclosed
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 — — US disclosed
WO-2017011776-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2017-01-19 — — WO disclosed
US-9113631-B2 1,3-diaryl-substituted heterocyclic pesticides E I DU PONT DE NEMOURS AND COMPANY (US) 2015-08-25 — — US disclosed
US-20140249025-A1 1,3-DIARYL-SUBSTITUTED HETEROCYCLIC PESTICIDES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2014-09-04 — — US disclosed
EP-2205610-B1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS HOFFMANN LA ROCHE (CH) 2013-11-20 — — EP disclosed
WO-2013063282-A1 1,3-DIARYL-SUBSTITUTED HETEROCYCLIC PESTICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2013-05-02 — — WO disclosed
US-8293735-B2 Thienopyrimidine derivatives as P13K inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2012-10-23 — — US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 — — US disclosed
EP-2205610-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 — — EP disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
WO-2008152394-A1 PHARMACEUTICAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2008-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 USP2 3820/4885SMN1; SMN2 3267/4885ACACB 2215/4885
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS PIK3CA, PIK3CD, PIK3CB USP2 3145/4885SMN1; SMN2 2967/4885ACACB 3511/4885
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 USP2 3932/4885SMN1; SMN2 1585/4885ACACB 3580/4885
US-20140249025-A1 1,3-DIARYL-SUBSTITUTED HETEROCYCLIC PESTICIDES DDT, CHRM1, CYP1B1 USP2 2480/4885SMN1; SMN2 2140/4885ACACB 3836/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 USP2 3820/4885SMN1; SMN2 3267/4885ACACB 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.